Cyclosporine is a drug used to help reduce the risk of rejection of organ and bone marrow transplants by the body. It is also used in clinical trials to make cancer cells more sensitive to anticancer drugs.
A topical eye emulsion consisting of cyclosporine (a medication used to reduce transplant rejections or to treat arthritis and psoriasis) may be a cost-effective treatment for dry eye syndrome that does not respond to other therapies, according to a report in the February issue of Archives of Ophthalmology.
New data from the JUPITER study demonstrated that Crestor (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by a dramatic 44% compared to placebo (p<0.001) among men and women with elevated hsCRP but low to normal cholesterol levels.
It has been common knowledge for a number of years that grapefruit juice can influence the absorption of certain drugs, potentially turning normal doses into toxic overdoses.
Scientists and consumers have known for years that grapefruit juice can increase the absorption of certain drugs - with the potential for turning normal doses into toxic overdoses.
An investigational antiviral drug currently undergoing human trials in Europe for treating Hepatitis C infections may have potential to reduce muscle cell damage in Duchenne and other forms of muscular dystrophy (MD).
Like fine china and crystal, which tend to be used sparingly, stem cells divide infrequently.
Novo Nordisk has announced that Norditropin (somatropin[rDNA origin] injection) received U.S. Food and Drug Administration (FDA) approval for the treatment of short stature in children with Noonan syndrome.
Sirion Therapeutics has announced that it has initiated new phase III clinical programs for two of its pipeline compounds, ST-601 (difluprednate) and ST-603 (cyclosporine).
Novagali Pharma has announced that the Company's Investigational New Drug Application (IND) to conduct a pivotal Phase III clinical trial of its Cyclosporine A ocular product, Nova22007, has been granted by the U.S. Food and Drug Administration (FDA).
Garcia, et al reported their experience with renal transplantation in 38 children (40 transplant), ages 1-5 years over a 16 year period.
Schering-Plough Corporation has announced that Schering-Plough K.K., the company's country operation in Japan, has received marketing approval for ZETIA (ezetimibe), a novel cholesterol-lowering agent that inhibits the absorption of cholesterol in the intestine.
New clinical trial results for heart transplant patients will be released at the upcoming International Society for Heart and Lung Transplantation (ISHLT) 27th Annual Meeting and Scientific Sessions at the Hilton San Francisco, April 25-28, 2007.
In good news for patients with stubborn cases of ulcerative colitis, a serious intestinal disorder, a new research review suggests that the drug infliximab can be a useful alternative if other treatments don't work.
Escherichia coli is a commensal bacterium, which lives peacefully in our digestive tract. However, certain strains are pathogenic and are frequently incriminated in a broad spectrum of infections, affecting both farmed animals and humans (diarrhoea, urinary tract infections, food poisoning, septicaemia, neonatal meningitis, etc.).
NICE has today issued guidance for the use of the targeted biological therapies, Enbrel (etanercept) and Raptiva (efalizumab), to treat adult patients with severe plaque psoriasis.
Howard Hughes Medical Institute (HHMI) researchers at Stanford University have found that they can increase bone mass in mice by tweaking the shape of a regulatory protein.
A single dose of adult donor stem cells given to animals that have neurological damage similar to that experienced by adults with a stroke or newborns with cerebral palsy can significantly enhance recovery from these types of injuries, researchers say.
A new study on children undergoing liver transplants found that although innovative transplant techniques have been developed in recent years, the waitlist times for pediatric transplant candidates have increased compared to the early 1990s.
A new study published in this month's issue of the Journal of the American Society of Nephrology shows that the risk of cancer in kidney transplant recipients was reduced by more than 50% at five years post transplantation in those patients who were treated with sirolimus following withdrawal of cyclosporine at three months.
According to the U.S. Food and Drug Administration a version of the diet drug Xenical, which will be available without a prescription, may be not be suitable for some people.